Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Inventiva (NASDAQ:IVA) through any online brokerage.
Other companies in Inventiva’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Inventiva has a consensus price target of $15.31.
The stock price for Inventiva (NASDAQ: IVA) is $3.6522 last updated September 30, 2026 at 7:21 PM EDT.
There are no upcoming dividends for Inventiva.
Inventiva does not have any upcoming earnings scheduled.
There is no upcoming split for Inventiva.
Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.